Amaranth Medical is a privately held medical device company that developed the FORTITUDE bioresorbable scaffold, designed to provide the strength of metal stents without leaving a permanent implant. Its lead product line includes a non‑drug‑eluting FORTITUDE scaffold previously evaluated in a 13‑patient study and a planned drug‑eluting FORTITUDE intended for further clinical evaluation. Results from the initial study, presented at TCT, suggested the scaffold maintained mechanical integrity with late lumen loss comparable to bare metal stents. The company announced an equity investment from Boston Scientific to advance an international clinical study, pursue a CE Mark application, and support development of a next‑generation FORTITUDE scaffold with thinner struts. Amaranth planned to begin enrolling a second cohort in 2014 to evaluate the drug‑eluting scaffold. The company is headquartered in Mountain View, California, with research and manufacturing operations in Singapore and at its Silicon Valley headquarters, and is led by CEO Kamal Ramzipoor. Prior investors named include Charter Life Sciences, Bio*One Capital, Philip Private Equity, DCP Management and Venstar Capital. Amaranth Medical is a Mountain View, California-based medical device company that has created a novel technology platform for the development and manufacturing of fully bioresorbable scaffolds. Led by Kamal Ramzipoor, General Manager and Chief Technical Officer, the company has research and manufacturing operations in Singapore and at its Silicon Valley headquarters. Its lead product is FORTITUDE™, a bioresorbable scaffold intended for treating coronary artery disease. The company intends to use the funds to develop the upcoming CE Mark clinical trial of FORTITUDE. Amaranth closed a $20m Series B financing to advance these clinical and development activities. The financing involved both new and existing investors, reflecting continued support for its platform.

Total raised

$20M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2013